NCT01545700

Brief Summary

The question of a possible hyperglycemic effect from single-dose dexamethasone is an important issue for clinicians managing patients in the intraoperative and postoperative periods. Recent evidence suggests that even moderate elevations in blood glucose levels may be associated with adverse events. The aim of this clinical investigation is to determine whether standard clinical doses of dexamethasone produce hyperglycemia in the perioperative period.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for phase_4

Timeline
Completed

Started Sep 2009

Typical duration for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2009

Completed
2.5 years until next milestone

First Submitted

Initial submission to the registry

February 27, 2012

Completed
9 days until next milestone

First Posted

Study publicly available on registry

March 7, 2012

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2012

Completed
3 months until next milestone

Results Posted

Study results publicly available

January 15, 2013

Completed
Last Updated

September 30, 2019

Status Verified

September 1, 2019

Enrollment Period

3.2 years

First QC Date

February 27, 2012

Results QC Date

November 9, 2012

Last Update Submit

September 12, 2019

Conditions

Keywords

dexamethasonehyperglycemiagynecologic surgery

Outcome Measures

Primary Outcomes (1)

  • Serum Blood Glucose Concentrations

    Serum blood glucose concentrations

    Patient were followed for the duration of hospitalization, for an average of 6 days

Secondary Outcomes (1)

  • Pain Scores

    Patients were followed for the duration of hospitalization, for an average of 6 days

Study Arms (6)

Control, saline 0-4 hours

PLACEBO COMPARATOR

2 cc of saline

Drug: Control-saline

Dexamethasone 4 mg, 0-4 hours

ACTIVE COMPARATOR

Dexamethasone 4 mg administered intraoperatively

Drug: Dexamethasone 4 mg

Dexamethasone 8 mg, 0-4 hours

ACTIVE COMPARATOR

Dexamethasone 8 mg administered intraoperatively

Drug: Dexamethasone 8 mg

Placebo Comparator saline 8-24 hours

PLACEBO COMPARATOR

placebo, 2 cc saline

Drug: Control saline

Dexamethasone 4 mg, 8-24 hours

ACTIVE COMPARATOR

Dexamethasone 4 mg administered intraoperatively

Drug: Dexamethasone 4 mg

Dexamethasone 8 mg, 8-24 hours

ACTIVE COMPARATOR

Dexamethasone 8 mg administered intraoperatively

Drug: Dexamethasone 8 mg

Interventions

Patients are randomized to receive saline 2 cc

Control, saline 0-4 hours

Patients randomized to receive dexamethasone 4mg and 1 cc saline

Dexamethasone 4 mg, 0-4 hours

Patients randomized to receive dexamethasone 8mg

Dexamethasone 8 mg, 0-4 hours

Patients are randomized to receive saline 2 cc

Placebo Comparator saline 8-24 hours

Eligibility Criteria

Age18 Years - 90 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients presenting for elective gynecologic surgery

You may not qualify if:

  • Age \< 18 or \> 90, patients receiving chronic or preoperative steroids,or allergy to dexamethasone.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

NorthShore University HealthSystem

Evanston, Illinois, 60201, United States

Location

MeSH Terms

Conditions

Postoperative ComplicationsHyperglycemia

Interventions

Dexamethasone

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and SymptomsGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

PregnadienetriolsPregnadienesPregnanesSteroidsFused-Ring CompoundsPolycyclic CompoundsSteroids, Fluorinated

Results Point of Contact

Title
Glenn S. Murphy, MD
Organization
NorthShore University HealthSystem

Study Officials

  • Glenn S Murphy, MD

    Endeavor Health

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director, Cardiac Anesthesia and Clinical Research

Study Record Dates

First Submitted

February 27, 2012

First Posted

March 7, 2012

Study Start

September 1, 2009

Primary Completion

November 1, 2012

Study Completion

November 1, 2012

Last Updated

September 30, 2019

Results First Posted

January 15, 2013

Record last verified: 2019-09

Locations